Gross Margin: A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. Calculated as: Gross Income / Total Revenues
Kyverna Therapeutics, Inc. (KYTX) Gross Margin data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-161.31M |
|
-- |
|
-- |
|
$169.83M |
|
$-169.83M |
|
$8.52M |
|
$-161.31M |
|
$-161.31M |
|
$-161.31M |
|
$-161.31M |
|
$-161.31M |
|
$-161.31M |
|
$-169.83M |
|
$-168.03M |
|
44.26M |
|
44.26M |
|
$-3.64 |
|
$-3.64 |
|
| Balance Sheet Financials | |
$282.95M |
|
$1.55M |
|
$10.87M |
|
$293.83M |
|
$36.49M |
|
$24.74M |
|
$25.06M |
|
$61.55M |
|
$232.28M |
|
$232.28M |
|
$232.28M |
|
60.39M |
|
| Cash Flow Statement Financials | |
$-153.71M |
|
$40.02M |
|
$141.17M |
|
$97.17M |
|
$124.64M |
|
$27.47M |
|
$10.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.75 |
|
-- |
|
-- |
|
0.10 |
|
0.11 |
|
|
Gross Margin |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-153.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-69.45% |
|
-69.45% |
|
-54.90% |
|
-62.76% |
|
$3.85 |
|
$-3.47 |
|
$-3.47 |
|